Evaluation of Endothelial Function by Flow-Mediated Dilation: a Comprehensive Review in Rheumatic Disease

Archivum Immunologiae et Therapiae Experimentalis

Volumn 65, Issue 6, 2017, Pages 463-475

  Moroni, Luca ^a,b   Selmi, Carlo ^a,c   Angelini, Claudio ^c   Meroni, Pier Luigi ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d Gaetano Pini Orthopaedic Hospital   (Italy)

Author keywords

Autoantibody; Cardiovascular risk; Chronic inflammation; Connective tissue disease; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL FUNCTION; ENDOTHELIUM CELL; EVALUATION STUDY; FLOW MEDIATED DILATION; FLOW-MEDIATED DILATION TEST; HUMAN; IMMUNE RESPONSE; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BLOOD FLOW VELOCITY; DILATATION; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PULSE WAVE; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKER; NITRIC OXIDE;

ATHEROSCLEROSIS; BIOMARKERS; BLOOD FLOW VELOCITY; DILATATION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NITRIC OXIDE; PULSE WAVE ANALYSIS; RHEUMATIC DISEASES;

EID: 85016636427     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-017-0465-7     Document Type: Review

References (156)

1. Akoglu H, Seringec N, Yildirim T et al (2013) Relationship between hemorheology and endothelial dysfunction in renal transplant patients receiving calcineurin inhibitors. J Nephrol 26:931–940
2. Altabas V, Altabas K, Kirigin L (2016) Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes. Mech Ageing Dev 159:49–62
3. Arosio E, De Marchi S, Rigoni A et al (2007) Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25:1273–1278
4. Astry B, Venkatesha SH, Moudgil KD (2013) Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis. Indian J Med Res 138:717–731
5. Barter PJ, Nicholls S, Rye KA et al (2004) Antiinflammatory properties of HDL. Circ Res 95:764–772
6. Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646
7. Bertoli AM, Alarcon GS, Calvo-Alen J et al (2006a) Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 54:1580–1587
8. Bertoli AM, Fernandez M, McGwin G Jr et al (2006b) Association of antioxidized low-density lipoprotein antibodies with vascular arterial events and renal manifestations in systemic lupus erythematosus patients: comment on the article by Frostegard et al. Arthritis Rheum 54:2035–2036
9. Bilsborough W, Keen H, Taylor A et al (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125–1131
10. Bosello S, Santoliquido A, Zoli A et al (2008) TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27:833–839
11. Bots ML, Westerink J, Rabelink TJ et al (2005) Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 26:363–368
12. Brennan FM, Chantry D, Jackson A et al (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247
13. Brey RL, Abbott RD, Curb JD et al (2001) beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 32:1701–1706
14. Bruno RM, Bianchini E, Faita F et al (2014) Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound 12:34
15. Capria A, De Nardo D, Baffetti FR et al (2010) Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 23:255–262
16. Celermajer DS (1997) Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30:325–333
17. Celermajer DS, Sorensen KE, Gooch VM et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet 340:1111–1115
18. Cerinic MM, Valentini G, Sorano GG et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295
19. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027
20. Cervera R, Serrano R, Pons-Estel GJ et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74:1011–1018
21. Chatterjee Adhikari M, Guin A, Chakraborty S et al (2012) Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 41:669–675
22. Chin CW, Chin CY, Ng MX et al (2014) Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. Rheumatol Int 34:1281–1285
23. Choi HK, Hernan MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177
24. Contessa C, Ramonda R, Lo Nigro A et al (2009) [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. Reumatismo 61:298–305
25. Conti F, Spinelli FR, Alessandri C et al (2014) Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 34:661–668
26. Corretti MC, Plotnick GD, Vogel RA (1995) Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 268(4 Pt):H1397–H1404
27. Corretti MC, Anderson TJ, Benjamin EJ et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265
28. Cugno M, Borghi MO, Lonati LM et al (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34:105–110
29. Daiber A, Steven S, Weber A et al (2016) Targeting vascular (endothelial) dysfunction. Br J Pharmacol. doi:10.1111/bph.13517
30. Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285–1295
31. del Rincon I, O’Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813–3822
32. DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 89:33D–38D
33. Dhawan V, Handu SS, Nain CK et al (2005) Chronic l-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. Mol Cell Biochem 269:1–11
34. Di Minno MN, Ambrosino P, Lupoli R et al (2015) Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med 47:346–353
35. Domsic RT, Dezfulian C, Shoushtari A et al (2014) Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol 32(6 Suppl 86):S-154–S-160
36. Doria A, Sherer Y, Meroni PL et al (2005) Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31(355–362):viii
37. dos Reis-Neto ET, da Silva AE, Monteiro CM et al (2013) Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus. Rheumatology 52:2187–2195
38. El-Magadmi M, Bodill H, Ahmad Y et al (2004) Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110:399–404
39. Erkan D (2006) Lupus and thrombosis. J Rheumatol 33:1715–1717
40. Fernandes JL, Mamoni RL, Orford JL et al (2004) Increased Th1 activity in patients with coronary artery disease. Cytokine 26:131–137
41. Fitzgerald O, Winchester R (2009) Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 11:214
42. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708–1714
43. Frech T, Walker AE, Barrett-O’Keefe Z et al (2015) Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 34:905–913
44. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003
45. Garg N, Krishan P, Syngle A (2016) Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function. Int J Angiol 25:222–228
46. George J, Harats D, Gilburd B et al (1999) Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99:2227–2230
47. Ghiadoni L, Huang Y, Magagna A et al (2001) Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 19(3 Pt 2):547–551
48. Ghiadoni L, Versari D, Magagna A et al (2007) Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 25:361–366
49. Ghiadoni L, Mosca M, Tani C et al (2008) Clinical and methodological aspects of endothelial function in patients with systemic autoimmune diseases. Clin Exp Rheumatol 26:680–687
50. Giannattasio C, Pozzi M, Gardinali M et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797
51. Gladman DD, Ang M, Su L et al (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135
52. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114:647–652
53. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 51:447–450
54. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:287–293
55. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR et al (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824
56. Gresele P, Migliacci R, Vedovati MC et al (2009) Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 123:444–451
57. Guin A, Chatterjee Adhikari M, Chakraborty S et al (2013) Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 43:48–54
58. Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890
59. Hardie KL, Kinlay S, Hardy DB et al (1997) Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. Austr N Z J Med 27:649–652
60. Hashimoto M, Akishita M, Eto M et al (1995) Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92:3431–3435
61. Hathaway CA, Heistad DD, Piegors DJ et al (2002) Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90:277–283
62. Hawkey CJ (2001) COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 15:801–820
63. Hollan I, Scott H, Saatvedt K et al (2007) Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 56:2072–2079
64. Hollan I, Bottazzi B, Cuccovillo I et al (2010) Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res 62:378–385
65. Hsue PY, Scherzer R, Grunfeld C et al (2014) Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 3:e001267
66. Hugh J, Van Voorhees AS, Nijhawan RI et al (2014) From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 70:168–177
67. Hurlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187
68. Jacobsson LT, Knowler WC, Pillemer S et al (1993) Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 36:1045–1053
69. Joannides R, Haefeli WE, Linder L et al (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91:1314–1319
70. Joannides R, Etienne I, Iacob M et al (2010) Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 23:1135–1143
71. Kerekes G, Soltész P, Szucs G et al (2011) Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 13:147–152
72. Kiss E, Soltesz P, Der H et al (2006) Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27:211–217
73. Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology 42:607–613
74. Kosch M, Hausberg M, Suwelack B (2003) Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 76:1516–1519
75. Krause D, Schleusser B, Herborn G et al (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21
76. Landewe RB, van den Borne BE, Breedveld FC et al (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355:1616–1617
77. Leeson P, Thorne S, Donald A et al (1997) Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 78:22–27
78. Li WQ, Han JL, Manson JE et al (2012) Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermat 166:811–818
79. Li J, Wang Y, Wang Y et al (2015) Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. J Mol Cell Cardiol 86:62–74
80. Liang KP, Liang KV, Matteson EL et al (2006) Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 54:642–648
81. Maas R, Schwedhelm E, Kahl L et al (2008) Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 54:292–300
82. Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415
83. Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60
84. Maradit-Kremers H, Nicola PJ, Crowson CS et al (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732
85. Matsuura E, Kobayashi K, Koike T et al (2002) Autoantibody-mediated atherosclerosis. Autoimmun Rev 1:348–353
86. Mazzoccoli G, Notarsanto I, de Pinto GD et al (2010) Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Int Emerg Med 5:495–500
87. McMahon M, Grossman J, FitzGerald J et al (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54:2541–2549
88. Mercanoglu F, Erdogan D, Oflaz H et al (2004) Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract 58:1003–1007
89. Meroni PL, Peyvandi F, Foco L et al (2007) Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5:2421–2428
90. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959
91. Murdaca G, Colombo BM, Cagnati P et al (2012) Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224:309–317
92. Nadareishvili Z, Michaud K, Hallenbeck JM et al (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 59:1090–1096
93. O’Leary DH, Bots ML (2010) Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J 31:1682–1689
94. Op den Buijs J, Musters M, Verrips T et al (2004) Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol 287:H2651–H2658
95. Orlandi A, Bochaton-Piallat ML, Gabbiani G et al (2006) Aging, smooth muscle cells and vascular pathobiology: implications for atherosclerosis. Atherosclerosis 188:221–230
96. Peretz A, Leotta DF, Sullivan JH et al (2007) Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord 7:11
97. Peters MJ, van Halm VP, Voskuyl AE et al (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61:1571–1579
98. Pierangeli SS, Chen PP, Raschi E et al (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34:236–250
99. Pingiotti E, Cipriani P, Marrelli A et al (2007) Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 1107:32–41
100. Ponthieux A, Herbeth B, Droesch S et al (2004) Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 172:299–308
101. Protogerou AD, Zampeli E, Fragiadaki K et al (2011) A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219:734–736
102. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090–3100
103. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939
104. Raitakari OT, Celermajer DS (2000) Flow-mediated dilatation. Br J Clin Pharmacol 50:397–404
105. Rajagopalan S, Somers EC, Brook RD et al (2004) Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103:3677–3683
106. Ramonda R, Puato M, Punzi L et al (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81:421–425
107. Reynolds JA, Robertson AC, Bruce IN et al (2014) Improving cardiovascular outcomes in rheumatic diseases: therapeutic potential of circulating endothelial progenitor cells. Pharmacol Ther 142:231–243
108. Rodriguez-Rodriguez L, González-Juanatey C, García-Bermúdez M et al (2011) CCR5Delta32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 13:R133
109. Rollando D, Bezante GP, Sulli A et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173
110. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406
111. Ronda N (2012) Differential impairment of serum cholesterol efflux capacity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 64:2
112. Rosato E, Barbano B, Gigante A et al (2013) Erectile dysfunction, endothelium dysfunction, and microvascular damage in patients with systemic sclerosis. J Sex Med 10:1380–1388
113. Roustit M, Simmons GH, Baguet JP et al (2008) Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 35:1576–1583
114. Ruiz-Irastorza G, Crowther M, Branch W et al (2010) Antiphospholipid syndrome. Lancet 376:1498–1509
115. Schuett H, Luchtefeld M, Grothusen C et al (2009) How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 102:215–222
116. Schurgers E, Billiau A, Matthys P (2011) Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-gamma. J Interferon Cytokine Res 31:917–926
117. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108
118. Sfikakis PP, Papamichael C, Stamatelopoulos KS et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985–1993
119. Sharma SK, Rathi M, Sahoo S et al (2016) Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis. Lupus 25:525–531
120. Shechter M, Shechter A, Koren-Morag N et al (2014) Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol 113:162–167
121. Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106
122. Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347
123. Sidiropoulos PI, Siakka P, Pagonidis K et al (2009) Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 38:6–10
124. Silva I, Teixeira A, Oliveira J et al (2015) Endothelial dysfunction and nailfold videocapillaroscopy pattern as predictors of digital ulcers in systemic sclerosis: a cohort study and review of the literature. Clin Rev Allergy Immunol 49:240–252
125. Sincer I, Kurtoğlu E, Yılmaz Çoşkun F et al (2015) Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study. Anatol J Cardiol 15:913–918
126. Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 11:390–400
127. Sodergren A, Karp K, Boman K et al (2010) Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 12:R158
128. Sokolove J, Brennan MJ, Sharpe O et al (2013) Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 65:1719–1724
129. Soltesz P, Dér H, Kerekes G et al (2009) A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 28:655–662
130. Soltesz P, Kerekes G, Dér H et al (2011) Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 10:416–425
131. Sorensen KE, Celermajer DS, Spiegelhalter DJ et al (1995) Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74:247–253
132. Stalc M, Tomsic M, Jezovnik MK et al (2011) Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. Clin Exp Rheumatol 29:616–623
133. Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702–1708
134. Szabo SJ, Sullivan BM, Peng SL et al (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21:713–758
135. Szucs G, Tímár O, Szekanecz Z et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis–relevance for prevention of vascular complications. Rheumatology 46:759–762
136. Tabas I, Garcia-Cardena G, Owens GK (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209:13–22
137. Taddei S, Ghiadoni L, Virdis A et al (1999) Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 100:1400–1405
138. Takahashi T, Asano Y, Amiya E et al (2012) Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 22:598–601
139. Takahashi T, Asano Y, Amiya E et al (2014) Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. Mod Rheumatol 24:106–111
140. Takase B, Uehata A, Akima T et al (1998) Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 82(1535–1539):A7–A8
141. Tincani A, Spatola L, Prati E et al (1996) The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species’ evolution. J Immunol 157:5732–5738
142. Turesson C, McClelland RL, Christianson TJ et al (2007) Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 66:70–75
143. Uehata A, Lieberman EH, Gerhard MD et al (1997) Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 2:87–92
144. Uyemura K, Demer LL, Castle SC et al (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97:2130–2138
145. Vaarala O, Alfthan G, Jauhiainen M et al (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925
146. Vaarala O, Manttari M, Manninen V et al (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91:23–27
147. Van Doornum S, McColl G, Jenkins A et al (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80
148. van Halm VP, Nurmohamed MT, Twisk JW et al (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151
149. Vanhoutte PM, Shimokawa H, Tang EH et al (2009) Endothelial dysfunction and vascular disease. Acta Physiol 196:193–222
150. Vaudo G, Marchesi S, Gerli R et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35
151. Veselinovic MV, Zivkovic VI, Toncev S et al (2012) Carotid artery intima-media thickness and brachial artery flow-mediated vasodilatation in patients with rheumatoid arthritis. VASA 41:343–351
152. Wang DG, Tang XW, Fan Y et al (2014) Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 37:2067–2075
153. Watanabe J, Charles-Schoeman C, Miao Y et al (2012) Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64:1828–1837
154. Weisman MH, Paulus HE, Burch FX et al (2007) A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 46:1122–1125
155. Wong M, Jiang BY, McNeill K et al (2007) Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 36:265–269
156. Yilmazer B, Sahin T, Unlu BO et al (2015) Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 35:1385–1392